AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00613184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Flocked swab (Nasal secretion sampling)
Description: Nasal Aspirate Nylon Flocked swab
Study NCT01963754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implants in Posterior Mandible
Description: Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
Study NCT01963754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subperiosteal 1:100.000 Articaine 4% epinephrine
Description: Administration of subperiosteal anesthesia for implant placement
Study NCT00613184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Flocked swab (Nasal secretion sampling)
Description: Nylon flocked swab Nasal Wash
Study NCT02797314 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone biopsies
Description: Bone biopsies
Study NCT05074225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrodesiccation and Curettage vs Excision
Description: Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
Study NCT03435068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic rotary bur
Description: Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
Study NCT03435068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
Study NCT03435068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Scalpel surgery were performed as control group (conventioanl group).
Study NCT01816048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
Study NCT00251719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Study NCT00251719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00251719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT01270737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole soy (soy flour)
Description: 40g soy flour per day for six months
Study NCT01816048 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Undergo NaF F18 PET/CT scan
Study NCT01816048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F NaF PET/CT scan
Study NCT01816048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F NaF PET/CT scan
Study NCT01270737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: daidzein
Description: 66mg daidzein per day for six months
Study NCT04314817 — intervention group
Intervention type: DRUG
Intervention: Any drug used to treat Covid-19
Description: lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
Study NCT05002348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupoint stimulation(Laser pen)
Description: Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
Study NCT03288844 — intervention group
Intervention type: PROCEDURE
Intervention: Ophthalmologic examinations
Description: epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
Study NCT03288844 — intervention group
Intervention type: OTHER
Intervention: Digital pictures
Description: Digital pictures 2D to be taken at each visit
Study NCT01270737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk powder
Description: 40g low-fat dry milk per day for six months
Study NCT03288844 — intervention group
Intervention type: OTHER
Intervention: QoL Questionnaires
Description: Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP16
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VP16
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
Study NCT01949129 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: 2 x 2Gy/day , 3 days (total 12Gy)
Study NCT01963754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional 1:100.000 Articaine 4% epinephrine
Description: Administer loco-regional anesthesia for implant placement in posterior mandible
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 2x5 mg/kg BW, 1 day
Study NCT00852306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte freezing
Description: retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
Study NCT00714129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (calorie restricted diet)
Description: Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
Study NCT00714129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (calorie restricted diet)
Description: Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
Study NCT00605735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-582949
Description: Tablets, Oral, 300 mg, once daily, 12 weeks
Study NCT00605735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, placebo, once daily, 12 weeks
Study NCT02273791 — intervention group
Intervention type: DRUG
Intervention: Estradiol valerate
Description: Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
Study NCT02273791 — intervention group
Intervention type: DRUG
Intervention: Sequential Clomiphene citrate and Gonadotropin
Description: Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
Study NCT04666415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
Study NCT04407494 — intervention group
Intervention type: BIOLOGICAL
Intervention: Reporting of anosmia, ageusia and other clinical symptoms
Description: Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
Study NCT03738020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF (YVOIRE classic)
Description: Treatment with HA IDF
Study NCT03738020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Treatment with Restylane
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14g/m² BS, 3 days
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² BS, 5 days
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: iV, dosage according therapeutic drug monitoring, 4 days
Study NCT03371342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin (Botulinum toxin type A)
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Thymoglobulin
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG Thymoglobulin
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Study NCT03371342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox(Botulinum toxin type A)
Study NCT01654523 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
Description: Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
Study NCT03094832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Study NCT01949129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grafalon
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Study NCT02381964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® (1RDA+CoQ10)
Study NCT02381964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® (3RDA)
Study NCT02381964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01514721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Timolol Maleate BAK-Free Fixed Combination
Description: Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
Study NCT00920478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musculoskeletal Ultrasound
Description: Gray scale and power doppler - to identify the presence of synovitis
Study NCT00920478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 28 Joint Disease Activity Score
Description: Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
Study NCT03693118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reh1,Reh2
Description: The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
Study NCT01663844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia w. extra support
Description: (Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
Study NCT01288157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Single dose of 100 mg subcutaneously
Study NCT01288157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Single dose of 50 mg subcutaneously
Study NCT02691026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT01663844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist guided Internet-CBT for insomnia
Description: (Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
Study NCT01663844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia and depression
Description: (Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
Study NCT01663844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Guided Internet-CBT for depression plus insomnia placebo
Description: (Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
Study NCT01882244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural Pathfinder Training
Description: Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
Study NCT01882244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
Study NCT00335998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00335998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00335998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study NCT04618588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Window Sinus Lift technique
Description: Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement
Study NCT00335998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo intracavitary or interstitial brachytherapy
Study NCT00335998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00335998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01796288 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: simultaneous radiotherapy
Study NCT01796288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Study NCT01796288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02193997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber
Study NCT02193997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02405988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Description: Administer 2,5 mL, dose intravenous naloxone 1,0 mg
Study NCT02405988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
Study NCT02765048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAIN Program
Description: Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
Study NCT01474304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
Study NCT02189798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode
Description: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
Study NCT02189798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS sound processor
Description: Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
Study NCT02593058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotions Program for Schizophrenia
Description: Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
Study NCT02593058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.